New drugs for Alzheimer's disease have received international attention

Medical Network October 29th The 11th Alzheimer's Disease Clinical Trial Conference was held in Barcelona, ​​Spain from 24th to 27th. On the 25th, Chinese scientists introduced the new domestic drug “Galome oligosaccharide (GV-971)”, which can significantly improve the cognitive dysfunction of patients with Alzheimer's disease and cause international concern.

Alzheimer's disease is a neurodegenerative disease characterized by memory impairment, aphasia, and changes in personality and behavior. The cause has not been known so far, so there has been no effective treatment.

According to reports, the clinical phase III trial of the drug was led by Xiao Shifu of Shanghai Mental Health Center, Zhang Zhenxin of Beijing Union Medical College Hospital and the main inventor of GV-971, and Shanghai Institute of Materia Medica, Chinese Academy of Sciences, led by 34 clinical trial sites in China. People participate together. The results showed that GV-971 achieved the expected results in the improvement of cognitive function, and it was safe and well tolerated.

Yan Meiyu said at the meeting: "GV-971 is a marine-derived oligosaccharide drug that exerts its anti-Alz by inhibiting the aggregation of beta amyloid, regulating the imbalance of intestinal flora, and reducing neuroinflammation. The role of Haimo disease."

Rachel Schindler, member of the Scientific Committee of the 11th Alzheimer's Disease Clinical Trial Conference, said at the meeting: "The results of this study are the closest successful anti-arc after the cholinesterase inhibitor has been on the market for more than 10 years. Alzheimer's disease drug."

Professor Eric Lehman, Executive Director of the Alzheimer's Institute of Banna, USA, said: "GV-971 is expected to be Alzheimer with its unique mechanism of action and encouraging cognitive improvement. Patients with a wide range of treatment options are expected to conduct more clinical studies of the drug and further validate its multi-target mechanism in clinical patients."

Jeffrey Cummings, a professor at the Cleveland Clinic in the United States, commented: "GV-971 can continuously and continuously improve the cognitive function of patients and provide a new solution for the treatment of Alzheimer's disease. We look forward to GV in the world in the future. -971 clinical trials to benefit patients worldwide as soon as possible."

Shanghai Green Valley Pharmaceutical Co., Ltd., which is involved in research and development, has submitted a new drug listing application in China on October 16 and plans to conduct global clinical trials in the future. Lu Songtao, chairman and general manager of Green Valley Pharmaceuticals, said that they look forward to working with global partners to continue fighting Alzheimer's disease.